✦ LIBER ✦

AUGT1A128 and 6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer

✍ Scribed by Kyu-pyo Kim, Ho-Sook Kim, Sun Jin Sym…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genotype-directed, dose-finding study of

✍ Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Phase I trial of dose escalation of cape

✍ Qiang Lin; Yue’e Liu; Chuilin Chang; Na Wang; Jingmei Fu; Xiaocang Ren; Xueji Ch 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 260 KB

Prognostic advantage of irinotecan dose

✍ Lu, Chien-Yu; Huang, Ching-Wen; Hu, Huang-Ming; Tsai, Hsiang-Lin; Huang, Chun-Mi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 455 KB

A phase II study of fixed-dose capecitab

✍ Rivory, L; Beale, P; Ong, S; Horvath, L; Clarke, S J; Sharma, R 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 90 KB

27 ORAL Phase I dose escalation study of

✍ M. De Jonge; N. Steeghs; J. Verweij; J.W.R. Nortier; F. Eskens; J. Ouwerkerk; C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB

3040 POSTER Optimal dose for an every 2

✍ F. Ciardiello; A. Cervantes; M. Vega-Villegas; E. Casado; E. Rodriguez-Braun; E. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

AUGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer